Q BioMed plans for clinical testing with its autism drug QBM-001

09:21 EDT 10 Oct 2018 | Proactive Investors

Q BioMed Inc (OTCQB: QBIO) CEO Denis Corin tells Proactive Investors' Christine Corrado the biomedical acceleration and development company is in the middle of preparing for the planned clinical trial of its drug candidate QBM-001, which is being tested to treat pediatric developmental nonverbal disorder in toddlers who suffer from autism spectrum disorders.

Corin added the company has recently reached a $4 million funding agreement with Yorkville Advisors Global, which will allow the biotech to reach additional commercial milestones.

Original Article: Q BioMed plans for clinical testing with its autism drug QBM-001


More From BioPortfolio on "Q BioMed plans for clinical testing with its autism drug QBM-001"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...